Jimmy Wei
Plus aucun poste en cours
Historique de carrière de Jimmy Wei
Anciens postes connus de Jimmy Wei
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
WI Harper Group, Inc.
 WI Harper Group, Inc. Investment ManagersFinance WI Harper Group, Inc. (WI Harper) is a venture capital firm founded in 1993 by Peter Liu. The firm is headquartered in San Francisco, California with additional offices in Beijing and Taipei. | Analyste en capital-investissement | - | 31/12/2007 |
| Private Equity Investor | - | 31/12/2007 | |
| Burrill China Group | Corporate Officer/Principal | - | - |
Hutchison MediPharma Ltd.
 Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Corporate Officer/Principal | 24/03/2010 | - |
Formation de Jimmy Wei
| University of Virginia | Masters Business Admin |
| North Carolina State University | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
| Chine | 3 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Private Equity Analyst | 1 |
| Private Equity Investor | 1 |
Sectorielle
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
WI Harper Group, Inc.
WI Harper Group, Inc. Investment ManagersFinance WI Harper Group, Inc. (WI Harper) is a venture capital firm founded in 1993 by Peter Liu. The firm is headquartered in San Francisco, California with additional offices in Beijing and Taipei. | Finance |
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Health Technology |
| Burrill China Group |
